Literature DB >> 20625819

Native MAG-1 antibody almost destroys human breast cancer xenografts.

William G North1, Roy H L Pang, Guohong Gao, Vincent A Memoli, Bernard F Cole.   

Abstract

A native form of mouse monoclonal IgG1 antibody called MAG-1, which recognizes an epitope on provasopressin, has been found to shrink and produce extensive necrosis of human breast tumor xenografts in nu/nu mice. We examined the ability of (90)Yttrium-labeled and native MAG-1 to affect the growth in nu/nu mice of cancer xenografts that were estrogen-responsive (from MCF-7 cells) and triple-negative (from MDA-MB231 cells). The growth rates of treated cells were compared to those receiving saline vehicle and those receiving (90)Yttrium-labeled and native forms of the ubiquitous antibody, MOPC21. Short-term treatments (4 doses over 6 days) not only with (90)Yttrium-MAG-1 but also native MAG-1 produced large reductions in size of rapidly growing tumors of both types, while both (90)Yttrium- MOPC21 and native MOPC21 had no effect. Native and (90)Yttrium-MAG-1 effects were similar, and arrested tumors recommenced growing soon after treatments stopped. Increasing native MAG-1 treatment to single dosing for 16 consecutive days shrank tumors of both types with no regrowth apparent over a 20-day post-treatment period of observation. Pathological examination of such tumors revealed they had undergone very extensive (>66%) necrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625819      PMCID: PMC4521588          DOI: 10.1007/s10549-010-1009-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  High-dose chemotherapy for triple negative breast cancer.

Authors:  U De Giorgi; G Rosti; L Frassineti; B Kopf; N Giovannini; F Zumaglini; M Marangolo
Journal:  Ann Oncol       Date:  2006-09-13       Impact factor: 32.976

Review 2.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

Authors:  G Valabrega; F Montemurro; M Aglietta
Journal:  Ann Oncol       Date:  2007-01-17       Impact factor: 32.976

3.  Trastuzumab--mechanism of action and use.

Authors:  Michalis V Karamouzis; Panagiotis A Konstantinopoulos; Athanasios G Papavassiliou
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

Review 4.  Aromatase inhibitors in the treatment of breast cancer.

Authors:  Robert W Brueggemeier; John C Hackett; Edgar S Diaz-Cruz
Journal:  Endocr Rev       Date:  2005-04-06       Impact factor: 19.871

5.  Targeting the neurophysin-related cell surface antigen on small cell lung cancer cells using a monoclonal antibody against the glycopeptide region (MAG-1) of provasopressin.

Authors:  Brendan P Keegan; Vincent A Memoli; William G North
Journal:  Mol Cancer Ther       Date:  2002-11       Impact factor: 6.261

6.  Immunoglobulin assembly in a mouse myeloma.

Authors:  D Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  1968-06       Impact factor: 11.205

7.  Immunohistochemical detection of NRSA on small cell lung cancer with a monoclonal antibody (MAG-1) that recognizes the carboxyl terminus of provasopressin.

Authors:  William G North; Vincent A Memoli; Brendan P Keegan
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-12

Review 8.  Gene regulation of vasopressin and vasopressin receptors in cancer.

Authors:  W G North
Journal:  Exp Physiol       Date:  2000-03       Impact factor: 2.969

9.  Interaction of vasopressin and oxytocin with human breast carcinoma cells.

Authors:  A H Taylor; V T Ang; J S Jenkins; J J Silverlight; R C Coombes; Y A Luqmani
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

10.  Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS).

Authors:  William G North; Wendy Wells; Michael J Fay; Rennie S Mathew; Edward M Donnelly; Vincent A Memoli
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more
  2 in total

1.  Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Authors:  Sonali Sinha; Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Vijayakumar R Kakade; Maura O' Neil; Robert H Weiss; Jonathan Enders; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Oncogene       Date:  2019-10-15       Impact factor: 9.867

2.  Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody.

Authors:  William G North; Bernard Cole; Bonnie Akerman; Roy H L Pang
Journal:  Front Oncol       Date:  2014-02-11       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.